Storia in 2 fonti

Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal

Biopharma deals roundup: Mentari's $200M migraine raise, Royalty Pharma's $425M ATTR-CM royalty buy, Dyne's $375M stock offering and Tikva Allocell's $8M Series A.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo5 g fa

Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal

Biopharma deals roundup: Mentari's $200M migraine raise, Royalty Pharma's $425M ATTR-CM royalty buy, Dyne's $375M stock offering and Tikva Allocell's $8M Series A.

originale

benzinga.com5 g fa

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.

Leggi questa versione → originale

Timeline cronologica

mercoledì 22 luglio 2026·endpoints.news
Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
Biopharma deals roundup: Mentari's $200M migraine raise, Royalty Pharma's $425M ATTR-CM royalty buy, Dyne's $375M stock offering and Tikva Allocell's $8M Series A.
mercoledì 22 luglio 2026·benzinga.com
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.